BridgeBio Reaches Agreement With U.S. Government To Expand Medicaid Access To Attruby

India, Sept. 1 -- BridgeBio Pharma, Inc. (BBIO), a commercial-stage biopharmaceutical company, announced a voluntary agreement with the U.S. government to expand access to its marketed medicines and lower costs for American patients.

Under the agreement, BridgeBio will expand state Medicaid access to Attruby (acoramidis) through the GENEROUS model. Attruby is approved for adults with transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalization.

BridgeBio will continue to offer Attruby through Medicare Part D without future pricing mandates. The company said the agreement builds on its existing patient access efforts, including ForgingBridges, its patient support program that prov...